Sign in
Elamipretide, a Mitochondrial-Targeted Drug, for the Treatment of Vision Loss in Dry AMD with High Risk Drusen
Michael J Allingham, MD, PhD
Annual Meeting Talks
2019
Clinical Trials Handbook
Nikolas JS London, MD, FACS, FASRS
Updates from the Field
2021
Gene Expression Profile and Local Tumor Recurrence of Irradiated Uveal Melanomas
Basil K Williams, MD
2022
Category: AMD-Neovascular